CSIMarket Company Name, Ticker, Customers, else..
 
Eton Pharmaceuticals Inc   (NASDAQ: ETON)
 
Price: $57.7500 $-2.15 -3.589%
Day's High: $59.94499969482422 Week Perf: -4.45 %
Day's Low: $ 57.30 30 Day Perf: 25.05 %
Volume (M): 130,782 52 Wk High: $ 66.37
Volume (M$): $ 0 52 Wk Avg: $26.30
Open: $59.88 52 Wk Low: $14.27



 Market Capitalization (Millions $) 1,893
 Shares Outstanding (Millions) 33
 Employees 44
 Revenues (TTM) (Millions $) 105
 Net Income (TTM) (Millions $) 13
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 15

Business Description


Eton Pharmaceuticals Inc is a specialty pharmaceutical company that focuses on developing and commercializing innovative treatments for various diseases and disorders. The company's main emphasis is on developing products that have a high need in the market, yet are underserved or have limited competition. Eton Pharmaceuticals aims to offer cost-effective solutions that improve patient outcomes and enhance quality of life. They have a strong pipeline of products in development across multiple therapeutic areas, including neurology, hospital, and rare diseases.


   Company Address: 21925 W. Field Parkway, Suite 235 Deer Park 60010 IL
   Company Phone Number: 787-7361   Stock Exchange / Ticker: NASDAQ ETON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -1.87%    
ALLR        2.84% 
MNOV        8.42% 
TEVA        0.7% 
• View Complete Report
   



Product Service News

Eton Pharmaceuticals Sets New Precedent in Rare Disease Treatment with Galzin® Acquisition,

Published Fri, Jan 3 2025 12:21 PM UTC

Eton Pharmaceuticals Takes Bold Step Forward in Fight Against Rare Diseases with Galzin Acquisition In a landmark move signaling its unwavering commitment to rare disease advocacy, Eton Pharmaceuticals, Inc. (NASDAQ: ETON) recently announced the acquisition of Galzin® (zinc acetate). This strategic decision, unveiled on January 3, 2025, positions Eton at the forefront of in...
Clinical Study

Eton Pharmaceuticals’ PKU GOLIKE Trial A Beacon of Hope for Patients and the Future of Metabolic Control

Published Sun, Dec 29 2024 3:26 PM UTC

In the rapidly evolving world of biopharmaceuticals, Eton Pharmaceuticals has recently set a new benchmark with the announcement of the final readout for its groundbreaking clinical trial of PKU GOLIKE. Garnering significant clinical and statistical improvement in metabolic control during prolonged fasting in patients with phenylketonuria (PKU), this trial’s findings promi...
Contract

Eton Pharmaceuticals Acquires Increlex to Enhance Treatment Options for Pediatric Patients with Severe IGF-1 Deficiency

Published Fri, Dec 20 2024 11:50 AM UTC

In December 2024, Eton Pharmaceuticals, Inc. a company renowned for its commitment to developing therapies for rare diseases, announced the successful acquisition of Increlex (mecasermin injection) from Ipsen S.A. This strategic move highlights Eton s dedication to addressing unmet medical needs in pediatric populations, specifically children suffering from severe primary in...
Contract

Eton Pharmaceuticals Expands Portfolio Through Acquisition of Increlex, Reinforcing Commitment to Rare Disease Patients

Published Thu, Oct 3 2024 10:30 AM UTC

In a significant move that underscores its commitment to patients with ultra-rare conditions, Eton Pharmaceuticals, Inc. has announced the acquisition of Increlex (mecasermin injection) from Ipsen. This strategic decision not only broadens Eton s product offerings but also aligns with its mission to develop and distribute medicines that can dramatically change lives.Increlex...
Management Announcement

Eton Pharmaceuticals' Hydrocortisone Oral Solution Prepares for FDA Decision as Share Price Rises

Published Mon, Jul 15 2024 8:05 PM UTC



In an exciting development for Eton Pharmaceuticals, the company recently announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ET-400, a Hydrocortisone Oral Solution. The Prescription Drug User Fee Act (PDUFA) target action date for the drug s approval is set for February 28, 2025. As Eton anticipates this dec...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 148.08
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 17.99
Price to Sales (Expected) -
Price to Book 40.65
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.59
Working Capital Ratio 1.52
Leverage Ratio (MRQ) 1.49
Total Debt to Equity 0.6
Interest Coverage (TTM) 7.77
Debt Coverage (TTM) 0.78

Per Share Current
Earnings (TTM) 0.39 $
Revenues (TTM) 3.21 $
Cash Flow (TTM) -
Cash 0.82 $
Book Value 1.42 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 2,392,705
Net Income per Employee (TTM) 288,364
Receivable Turnover Ratio (TTM) 6.67
Inventory Turnover Ratio (TTM) 3.11
Asset Turnover Ratio (TTM) 1.03

Profitability Ratios Current
Gross Margin (MRQ) 67.61 %
Operating Margin (MRQ) 34.04 %
Net Margin (MRQ) 30.8 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 0.49 %

Management Effectiveness Current
Return On Assets (TTM) 12.37 %
Return On Investment (TTM) 21.31 %
Return On Equity (TTM) 40.13 %
Dividend Yield -
Pay out Ratio (TTM) -



Eton Pharmaceuticals Inc's Segments
Product    164.56 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.